CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Down 97.9% in January

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the target of a large decline in short interest in January. As of January 15th, there was short interest totalling 150,000 shares, a decline of 97.9% from the December 31st total of 7,300,000 shares. Based on an average daily volume of 906,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 16.5% of the shares of the stock are sold short.

Insiders Place Their Bets

In other CERo Therapeutics news, major shareholder Bioventures Opportunities G. Yk sold 8,505 shares of CERo Therapeutics stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $11.00, for a total value of $93,555.00. Following the sale, the insider now owns 205,333 shares of the company’s stock, valued at $2,258,663. The trade was a 3.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold a total of 64,300 shares of company stock worth $529,409 in the last 90 days. 18.00% of the stock is currently owned by corporate insiders.

CERo Therapeutics Stock Performance

Shares of CERO opened at $1.94 on Thursday. CERo Therapeutics has a fifty-two week low of $1.76 and a fifty-two week high of $1,280.00. The company’s fifty day moving average is $8.00 and its 200 day moving average is $11.36.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.